Chikungunya Virus VLP Antibody (AG7-2-A7-E10) - Azide and BSA Free

Novus Biologicals, part of Bio-Techne | Catalog # NBP3-14852

Novus Biologicals, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
NBP3-14852-0.1mg
NBP3-14852-0.5mg
Print Quote
Bulk Order
100% Guarantee

Key Product Details

Species Reactivity

Virus

Applications

ELISA, Western Blot

Label

Unconjugated

Antibody Source

Monoclonal Mouse IgG Clone # AG7-2-A7-E10

Format

Azide and BSA Free

Concentration

1 mg/ml

View all Chikungunya Virus VLP Antibodies »

Product Specifications

Immunogen

An equal mix of Chikungunya, Mayaro and O'nyong'nyong VLPs (comprising E1, E2 and capsid proteins), produced in HEK293 cells

Reactivity Notes

Chikungunya

Specificity

This antibody recognises Chikungunya virus VLPs containing E1, E2 and capsid proteins. Antibody shows some cross-reactivity with Mayaro Envelope protein in ELISA but not with O'nyong'nyong virus or Ross River virus VLPs.

Clonality

Monoclonal

Host

Mouse

Isotype

IgG

Description

Addition of 0.09% w/v sodium azide is recommended for long term storage at +4C.

Scientific Data Images for Chikungunya Virus VLP Antibody (AG7-2-A7-E10) - Azide and BSA Free

Western Blot: Chikungunya Virus VLP Antibody (AG7-2-A7-E10) [NBP3-14852]

Western Blot: Chikungunya Virus VLP Antibody (AG7-2-A7-E10) [NBP3-14852]

Western Blot: Chikungunya Virus VLP Antibody (AG7-2-A7-E10) [NBP3-14852] - 100ng of each antigen was used for SDS-PAGE, in non-reduced form. Proteins were transferred using Transblot for 7 min. at 25V. 5% dry milk in PBS-T was used as blocking buffer and dilution buffer for antibodies. Primary antibody (Chikungunya Virus VLP Antibody) and goat anti-mouse-IgG-HRP secondary antibody were used at 1:1000. All steps were carried out for 1h at room temperature with gentle rocking. KPL Membrane TMB was used for detection. Development time 30 sec.
ELISA: Chikungunya Virus VLP Antibody (AG7-2-A7-E10) [NBP3-14852]

ELISA: Chikungunya Virus VLP Antibody (AG7-2-A7-E10) [NBP3-14852]

ELISA: Chikungunya Virus VLP Antibody (AG7-2-A7-E10) [NBP3-14852] - Plate was coated with 0.5ug/ml of antigens in 1X DPBS overnight at 2-8C. Blocked for 1.5h using 1%BSA/DPBS.300ul/well. Washed plate 3X using Tris wash buffer. Added 100ul of prepared antibody dilutions. Incubated for 2h at RT at 800rpm.Washed plate 3X using Tris wash buffer. Added 100ul of Goat anti mouse IgG HRP antibody (1:5000 dilution) to all the wells and incubated for 1h at RT, 800rpm. Washed plate 4X using Tris wash buffer. Added 100ul HKTMB and incubated for ~2min. at RT. Added 100ul 1M HCl to stop the reaction and read the plate at 450nm.

Applications for Chikungunya Virus VLP Antibody (AG7-2-A7-E10) - Azide and BSA Free

Application
Recommended Usage

ELISA

Optimal dilutions of this antibody should be experimentally determined.

Western Blot

Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Antibody recognises VLPs for CHIKV, ONNV, MAYV and RRV in non-reducing Western blot. Antibody not suitable for Western blot in reducing conditions.

Formulation, Preparation, and Storage

Purification

Protein G purified

Formulation

PBS pH 7.4

Format

Azide and BSA Free

Preservative

No Preservative

Concentration

1 mg/ml

Shipping

The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.

Background: Chikungunya Virus VLP

Chikungunya virus (CHIKV) belongs to the family of alphaviruses and is transmitted by Aedes mosquitoes resulting in infection characterized by symptoms including arthritis-like joint pain and inflammation, fever, rash, and headache (1-3). The CHIKV genome consists of an 11.8 kilobase (kb) positive-sense, single-stranded RNA virus that has two open reading frames (ORFs) (1-3). The first ORF at the 5' end encodes a 2472 amino acid (aa) nonstructural polyprotein and the ORF at the 3' end encodes a 1244 aa structural polyprotein (1-3). The polyproteins generate four nonstructural proteins (nsP1-4) and five structural proteins: capsid (C), envelope E1, E2, E3, and 6K (1-3). The nonstructural proteins comprise CHIKV's RNA replicase (1,2). Structurally, CHIKV has a diameter of ~65 nm and the virion is formed by an icosahedral nucleocapsid shell encapsulating genomic RNA and surrounded by a lipid bilayer envelope (2,3).

Although analysis suggests CHIKV originated in Africa over 500 years ago, first infections weren't reported until the 1950s (1-3). CHIKV has evolved three distinct genotypes, or strains, based on location, termed West African (WA), East/Central/Southern African (ECSA), and Asian (2-3). The WA strain has been most closely associated with enzootic transmission whereas the ECSA strain contributes more to urban epidemics (2). Nonhuman primates are the primary reservoir for the viral host with transmission occurring via mosquitos biting and infecting humans (1-3). Upon acute infection, the virus replicates in cells including fibroblasts and macrophages resulting in innate immune response in infected tissues characterized by infiltrating cells like macrophages, monocytes, natural killer (NK) cells, and lymphocytes (2,3). Infection results in increased production of proinflammatory cytokines such as interferon alpha (IFN-alpha) and interleukin 6 (IL-6), chemokines, and growth factors (2,3). Physical manifestations of infection are high fever, polyarthralgia, headache, arthritis, and rash (1-3). CHIKV symptoms can be confused with other infections like those from dengue fever and Zika virus (1-3). There are no specific antivirals or vaccines for CHIKV, but rather symptoms are treated with antipyretics and non-steroidal anti-inflammatory drugs (NSAIDs) (2,3). While in vitro culture models and in vivo rodent and non-human primate models have been used to study CHIKV pathogenesis and advance our knowledge of the disease, the specific cellular mechanisms are not fully understood (3).

References

1. Vu DM, Jungkind D, Angelle Desiree LaBeaud. Chikungunya Virus. Clin Lab Med. 2017;37(2):371-382. https://doi.org/10.1016/j.cll.2017.01.008

2. Silva LA, Dermody TS. Chikungunya virus: epidemiology, replication, disease mechanisms, and prospective intervention strategies. J Clin Invest. 2017;127(3):737-749. https://doi.org/10.1172/JCI84417

3. Ganesan VK, Duan B, Reid SP. Chikungunya Virus: Pathophysiology, Mechanism, and Modeling. Viruses. 2017;9(12):368. Published 2017 Dec 1. https://doi.org/10.3390/v9120368

Additional Chikungunya Virus VLP Products

Product Documents for Chikungunya Virus VLP Antibody (AG7-2-A7-E10) - Azide and BSA Free

Product Datasheets

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Download SDS

Product Specific Notices for Chikungunya Virus VLP Antibody (AG7-2-A7-E10) - Azide and BSA Free

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Privacy and Cookie Policy
Site Map
© Copyright 2024 Bio-Techne. All Rights Reserved.